Wedbush Initiates Novavax At Outperform

Analysts at Wedbush initiated coverage on shares of Novavax

with a Outperform rating. The target price for Novavax is set to $10. Novavax shares have jumped 43.59% over the past 52 weeks, while the S&P 500 index has gained 17.63% in the same period. Novavax's shares rose 0.67% to $4.51 in after-hours trading.